Lack of Effect on Survival of High-Dose Acyclovir and Zidovudine Compared with Zidovudine Alone for Acquired Immunodeficiency Syndrome
暂无分享,去创建一个
A. Collier | L. Corey | D. Schoenfeld | MartinS. Hirsch | L. Davis | C. M. van der Horst | K. Stanley
[1] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1998: updated recommendations of the International AIDS Society-USA Panel. , 1997, JAMA.
[2] Henry J. Kaiser,et al. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[3] J. Neaton,et al. Acyclovir use and survival among human immunodeficiency virus-infected patients with CD4 cell counts of < 500/mm3. The Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA). , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[4] S. Hammer,et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. , 1998, JAMA.
[5] N. Heveker,et al. Identification of a chemokine receptor encoded by human cytomegalovirus as a cofactor for HIV-1 entry. , 1997, Science.
[6] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[7] R. Chaisson,et al. Acyclovir in combination with zidovudine does not prolong survival in advanced HIV disease. , 1997, Antiviral therapy.
[8] J. Kahn,et al. HIV-1 protease inhibitors. A review for clinicians. , 1997 .
[9] J. Kahn,et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. , 1996, The Journal of infectious diseases.
[10] J. Goedert,et al. Serum HIV-1 RNA levels and time to development of AIDS in the Multicenter Hemophilia Cohort Study. , 1996, JAMA.
[11] Richard D Moore,et al. Lack of Association between Acyclovir Use and Survival in Patients with Advanced Human Immunodeficiency Virus Disease Treated with Zidovudine , 1995 .
[12] C. Sabin,et al. The effect of CMV infection on progression of human immunodeficiency virus disease in a cohort of haemophilic men followed for up to 13 years from seroconversion , 1995, Epidemiology and Infection.
[13] J. Phair,et al. Prognostic factors in human immunodeficiency virus-positive patients with a CD4+ lymphocyte count < 50/microL. , 1995, The Journal of infectious diseases.
[14] J. Phair,et al. The Effect of the Interaction of Acyclovir with Zidovudine on Progression to AIDS and Survival: Analysis of Data in the Multicenter AIDS Cohort Study , 1994, Annals of Internal Medicine.
[15] B. Gazzard,et al. Effects of high‐dose oral acyclovir on herpesvirus disease and survival in patients with advanced HIV disease: a double‐blind, placebo‐controlled study , 1994 .
[16] S. Allen,et al. Co-infection and synergy of human immunodeficiency virus-1 and herpes simplex virus-1 , 1994, The Lancet.
[17] D. Faulds,et al. Aciclovir. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic efficacy. , 1994, Drugs.
[18] M. Moroni,et al. The efficacy and safety of zidovudine alone or as cotherapy with acyclovir for the treatment of patients with AIDS and AIDS‐related complex: a double‐blind, randomized trial , 1993 .
[19] S. Hammer,et al. Activation of human immunodeficiency virus by herpes simplex virus. , 1992, The Journal of infectious diseases.
[20] J. Pagano,et al. Inhibition of Human Immunodeficiency Virus Type 1 Replication by Guanosine Analogues and Lack of Synergistic Antiviral Effect of Acyclovir with 3′-azido-3′-deoxythymidine , 1991 .
[21] D. Richman,et al. A pilot study of low-dose zidovudine in human immunodeficiency virus infection. , 1990, The New England journal of medicine.
[22] J. Laurence,et al. Molecular interactions among herpesviruses and human immunodeficiency viruses. , 1990, The Journal of infectious diseases.
[23] P. Griffiths,et al. CYTOMEGALOVIRUS INFECTION AND PROGRESSION TOWARDS AIDS IN HAEMOPHILIACS WITH HUMAN IMMUNODEFICIENCY VIRUS INFECTION , 1989, The Lancet.
[24] M. Hirsch,et al. Bidirectional interactions between human immunodeficiency virus type 1 and cytomegalovirus. , 1988, The Journal of infectious diseases.
[25] D. Markovitz,et al. An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat. , 1988, Proceedings of the National Academy of Sciences of the United States of America.
[26] E. Huang,et al. Immediate-early gene region of human cytomegalovirus trans-activates the promoter of human immunodeficiency virus. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[27] P. Luciw,et al. Transactivation of human immunodeficiency virus by herpesviruses. , 1987, Oncogene.
[28] Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases. , 1987, MMWR supplements.
[29] H. Mitsuya,et al. Strategies for antiviral therapy in AIDS , 1987, Nature.
[30] J. Sodroski,et al. Herpes simplex virus type-1 can reactivate transcription of latent human immunodeficiency virus , 1987, Nature.